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Abstract
Objectives: To investigate the safety and immunogenicity of a booster BCG vaccination delivered intradermally in healthy,
BCG vaccinated subjects and to compare with a previous clinical trial where BCG vaccinated subjects were boosted with a
new TB vaccine, MVA85A.
Design: Phase I open label observational trial, in the UK. Healthy, HIV-negative, BCG vaccinated adults were recruited and
vaccinated with BCG. The primary outcome was safety; the secondary outcome was cellular immune responses to antigen
85, overlapping peptides of antigen 85A and tuberculin purified protein derivative (PPD) detected by ex vivo interferon-
gamma (IFN-c) ELISpot assay and flow cytometry.
Results and Conclusions: BCG revaccination (BCG-BCG) was well tolerated, and boosting of pre-existing PPD-specific T cell
responses was observed. However, when these results were compared with data from a previous clinical trial, where BCG
was boosted with MVA85A (BCG-MVA85A), MVA85A induced significantly higher levels (.2-fold) of antigen 85-specific
CD4+ T cells (both antigen and peptide pool responses) than boosting with BCG, up to 52 weeks post-vaccination
(p = 0.009). To identify antigen 85A-specific CD8+ T cells that were not detectable by ex vivo ELISpot and flow cytometry,
dendritic cells (DC) were used to amplify CD8+ T cells from PBMC samples. We observed low, but detectable levels of
antigen 85A-specific CD8+ T cells producing IFNc (1.5% of total CD8 population) in the BCG primed subjects after BCG
boosting in 1 (20%) of 5 subjects. In contrast, in BCG-MVA85A vaccinated subjects, high levels of antigen 85A-specific CD8+
T cells (up to 14% total CD8 population) were observed after boosting with MVA85A, in 4 (50%) of 8 subjects evaluated. In
conclusion, revaccination with BCG resulted in modest boosting of pre-existing immune responses to PPD and antigen 85,
but vaccination with BCG-MVA85A induced a significantly higher response to antigen 85 and generated a higher frequency
of antigen 85A-specific CD8+ T cells.
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Introduction
It is estimated that one third of the world’s population is infected
with Mycobacterium tuberculosis (M. tb.) [1]. In most infected
individuals the host response contains this infection, or may result
in pathogen clearance. However, the global burden of disease
remains a significant problem. In 2007, there were estimated to be
9.2 million new cases of tuberculosis (TB) and in 2006, there were
0.5 million cases of multi-drug resistant TB [1]. The only available
vaccine against TB, Mycobacterium bovis Bacille Calmette-Guerin
(BCG), has variable efficacy. When BCG is administered at birth,
it confers consistent and reliable protection against disseminated
disease in childhood in the developing world [2,3]. However, BCG
fails to protect against pulmonary disease in these regions [4]. Any
improved vaccine regime against TB should include BCG,
administered in infancy, in order to retain the protective effects
against severe childhood disease [5,6,7].
Revaccination with BCG in adolescence has been routine
practice in many countries throughout the world, with evidence to
suggest that it confers improved protection against diseases such as
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TB meningitis [2] and leprosy [8]. In a large clinical trial of BCG
revaccination with over 200,000 children in Brazil, no enhanced
protective effect of boosting with BCG against pulmonary disease
was observed [9]. In light of this and other studies, revaccination is
not recommended by the WHO [10].
The immunological markers of protection against TB have not
yet been defined. However, immunity to M.tb. is dependent on
the generation of a Th1-type cellular immune response. Secretion
of IFNc is central to the activation of M.tb-infected macrophages
and the measurement of IFNc release from antigen-specific T
cells provides the best available immunological correlate of
protection against TB [11,12,13]. TB is the commonest HIV-
related disease and the most frequent cause of mortality [1]. The
annual risk of developing TB disease from reactivation of latent
M.tb infection in those co-infected with HIV is 5–15% annually,
compared to a 5–10% lifetime risk in immunocompetant
individuals [14,15]. In addition to the importance of CD4+ T
cells in protective immunity, CD8+ T cells are also important in
the control of M.tb infection. CD8+ T cells may be of greater
importance during the latent stages of M.tb infection, by
maintaining control of slowly replicating bacteria, rather than
in acute infection [16,17]. Improved induction, activation, or
functionality of TB-specific CD8+ T cells may enhance protective
immunity against TB [18].
We have developed a new vaccine, Modified Vaccinia Ankara
expressing antigen 85A (MVA85A) using a recombinant viral
vector system that is designed to induce and amplify the cellular
immune response. This vaccine has been developed as a booster
vaccine for BCG. Antigen 85A is an enzyme (mycolyl-
transferase) involved in cell wall biosynthesis, is highly conserved
in all mycobacterial species, and is present in all strains of BCG
[19,20]. Antigen 85A is immunodominant in animal and human
studies [21,22,23], and immunization with antigen 85A con-
ferred significant protection against M.tb challenge [21,22,23].
Boosting BCG with MVA85A induces high levels of antigen
specific IFNc secreting CD4+ and CD8+ cells and enhanced
protection against M.tb challenge when administered intranasally
to mice. In larger animals enhanced protection was observed
when MVA85A was administered intradermally to boost BCG
in non human primates (Verreck F et al, submitted) and also to
cattle where protection against M. bovis challenge was enhanced
(Vordermeier M et al, submitted). In a series of clinical trials we
have shown that MVA85A is effective at inducing high levels of
antigen specific CD4+ T cells when given alone or as a boost to
BCG induced immune responses [24]. However, detecting TB-
specific CD8+ T cells in peripheral blood mononuclear cells
(PBMC) samples from these clinical trials proved to be difficult.
Using ex vivo ELISpot assays and PBMC based flow cytometry,
no antigen specific CD8+ T cell responses were detected either
before or after MVA85A vaccination in any of the studies to
date. In other work, dendritic cells (DC) have been employed as
professional antigen presenting cells, to increase the sensitivity of
CD8+ T cell detection. This is due to the high levels of MHC I
and MHC II, co-stimulatory molecules and relevant cytokine
profile expressed by mature DC which facilitates expansion of
antigen-specific T cell population that otherwise may not be
detected [25,26,27,28].
The aim of the clinical trial presented here was to investigate the
safety and immunogenicity of boosting BCG vaccinated subjects
with BCG, and to compare these results with data from previous
trials where BCG vaccinated subjects had been boosted with
MVA85A [24]. In addition, the particular immunological focus
was to establish a methodology for detecting antigen specific
CD8+ T cell responses in these subjects.
Methods
Consort flowcharts for each of the two trials discussed here are
presented in Figure 1. The protocol for this trial and supporting
CONSORT checklist are available as supporting information; see
Checklist S1 and Protocol S1.
Participants
Subjects were recruited for both clinical trials under protocols
approved by the Oxfordshire Research Ethics Committee and
enrolled only after obtaining written informed consent. Follow up
was for 24 weeks; however protocols were amended during the
trial so that subjects still living in the area were invited for a week
52 assessment. The trials reported here were open label
observational trials.
Subjects enrolled in the clinical trials were all healthy and had
previously been vaccinated with BCG. This was confirmed visually
by the presence of a BCG scar. They were all seronegative for
HIV, HBV and HCV at screening, and routine laboratory
haematology and biochemistry were performed prior to vaccina-
tion. All values were within normal limits. All subjects had a Heaf
test and anyone with a Heaf test score of greater than Grade 2 was
excluded. All subjects were negative for the M.tb -specific antigens
ESAT6 and CFP10, as determined by an ex vivo ELISpot assay.
There were 14 subjects eligible for enrolment into the BCG-
BCG trial with a median time interval of 12 years from their first
BCG vaccination. The median age of subjects was 28 years (range
19 to 51 years). Subjects in the BCG-MVA85A trial were from a
previously reported study (n= 17) [24], with an additional 4
subjects subsequently recruited into the BCG-MVA85A group. All
21 subjects were used in the analysis for this paper. Similar
inclusion/exclusion criteria were applied to subjects recruited to
the BCG-BCG and BCG-MVA85A studies [24]. The median
interval period between BCG vaccination and boosting with
MVA85A was 18 years in this group, and the median age of
subjects was 31 years (range 22 to 54 years). Demographic
information on all the subjects is summarised in Table 1.
All subjects completed a diary card recording local and systemic
adverse events and body temperature for 7 days following
vaccination. In addition, solicited adverse events were collected
at each clinic visit.
Interventions
In the BCG-BCG study, volunteers were vaccinated with BCG
(a single immunisation with BCG (BCG Denmark, Statens Serum
Institute, Copenhagen, Denmark), 100 ml administered intrader-
mally over the deltoid region (n= 14)). In the BCG-MVA85A
study, subjects were vaccinated intradermally with a single
immunisation of 56107 pfu MVA85A [24].
Immunogenicity Analyses
ELISpot Analysis. A standardised ex vivo IFNc ELISpot assay
was performed on PBMC taken at the following time points: at
screening (prior to the Heaf test), and then at 1, 4, 8, 12, and 24
weeks after vaccination on fresh PBMC from subjects in both trial
groups. Blood was also taken at 52 weeks after vaccination in those
subjects still residing in the area [24]. Briefly, 300,000 fresh
PBMCs per well were plated directly onto the ELISpot plate
(MAIP, Millipore) in the presence of either Tuberculin Purified
Protein Derivative (PPD) at 20 mg/ml, purified antigen 85
complex (10 mg/ml), or antigen 85A pooled peptides (7 pools of
9–10 15-mer peptides spanning the length of antigen 85A, which
overlapped by 10 amino-acids). The final concentration of each
peptide in the well was 10 mg/ml. The PBMC were incubated
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with antigen (PPD, antigen 85, or antigen 85A peptide pools) for
18 hours at 37uC. Streptokinase/Streptodornase and PHA were
used in all assays as positive controls and cells and media alone as
the negative control. Assays were performed in duplicate and the
results were averaged.
The ELISpot data were analysed by subtracting the background
counts (mean number of spots in the medium and cells alone
control wells) from the mean number of spots in wells with antigen
and cells, using an AID ELISpot 04 reader (AID Diagnostika
GmbH, Strassberg, Germany). Counts of less than 5 spots/well
were considered as negative. A well was considered positive if the
count was at least twice that in the negative control wells and at
least 5 spots more than the negative control wells. For the peptide
pool wells, the results were summed across all the peptide pools
(SPP) for each volunteer, at each time point. This will count twice
a T cell that responds to any of the 10-mer overlap regions that
occur in two pools with adjacent peptides, as each pool contains
non-overlapping peptides.
An area under the curve (AUC) analysis for IFNc ELISpot
responses was performed to compare BCG - BCG and BCG -
MVA85A vaccine regimens over time (up to 52 weeks).
Dendritic Cell Mediated CD8+ T Cell Amplification
The flow cytometry assays were performed on cryopreserved
PBMC obtained from subjects in both the BCG-BCG and BCG-
MVA85A groups at screening (prior to the tuberculin skin test),
and then at 1, 4, 8, 12 and 24 weeks after vaccination allowing
comparability between groups. In this assay, PBMC were co-
cultured with monocyte derived dendritic cells (DC) to enhance
the detection of ex vivo CD8+ T cell responses.
Table 1. Demographic Details of Subjects in BCG-BCG and
BCG-MVA85A Trials.
BCG–BCG (n=14)
BCG–MVA85A
(n=21)
Gender Male 29% (4) Male 48% (10)
Female 71% (10) Female 52% (11)
Age minimum – maximum
(median) years
Range 19–51 (28) Range 22–54 (31)
Years post BCG prime
minimum – maximum
(median)
Range 7–38 (12) Range 1–38 (18)
Country of birth
UK 93% (13) 86% (14)
Africa 0% 12% (2)
Other 7% (1) 24% (5)
Healthcare worker 36% (5) 29% (6)
Significant travel history 21% (3) 10% (2)
doi:10.1371/journal.pone.0005934.t001
Figure 1. Consort Flowcharts for (a) BCG-BCG and (b) BCG-MVA85A Vaccination Regimens After 52 Weeks Post-Vaccination.
doi:10.1371/journal.pone.0005934.g001
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DC were produced using the standard method of culturing with
IL-4 and GMCSF [29]. At day 5 they were activated with 10 ng/
ml LPS. At 16 hour post-activation, the DC were washed, peptide-
pulsed for 45 minutes, and washed again. Preliminary experiments
performed with DC pulsed with BCG showed no detectable CD8+
T cell response in the BCG-BCG regime and so this was not
investigated further. PBMC were co-cultured in 24-well plates at a
ratio of 15:1 (PBMC:DC) in the presence of IL-7 at 25 ng/ml on
day 1, then IL-2 was added at 0.5 ng/ml on day 3, and
subsequently on day 7 and day 10. The culture was washed on day
13 and peptide re-stimulation (10 mg/ml) was performed on day
14, alongside PHA and unstimulated cells. Brefeldin A was added
after 4 hours and after a further 12 hours intracellular cytokine
staining was performed to detect IFNc using the Becton Dickinson
intracellular cytokine staining kit with GolgiPlugTM, according to
the manufacturer’s protocol.
An HLA-A2 specific CD8+ immunodominant antigen 85A
peptide pentamer, KLIANNTRV [30] was selected as this has
previously been shown to be recognised in BCG vaccinated
subjects. A previously defined HLA-A2 restricted CD8+ T cell
epitope was selected as HLA-A2 is the most common HLA Class I
antigen and this therefore enabled us to analyse the maximum
number of subjects using a single epitope, KLIANNTRV. To
evaluate and quantify CD8+ T cell responses, 5 subjects in the
BCG-BCG trial and 8 subjects in the BCG-MVA85A trial all of
whom were HLA-A2 positive were analysed.
Tetramers for EBV (EBNA 3A, HLA-B35-restricted YPL-
HEQHGM) and HIV epitopes (gag; p17 HLA-A24-restricted
KYRLKHLVW and p46 HLA-A6802-restricted ETAYFILKL)
were used as a positive and negative control (for short term culture
conditions), respectively [27,28,31].All antigens were used at
10 mg/ml.
Cells were incubated with KLIANNTRV pentamer labelled
with APC for 60 minutes at 37uC. Cells were then cooled to 5uC
and incubated with PE-conjugated CD8 mAb (Becton Dickinson)
for 30 minutes, washed and incubated with FITC-conjugated
IFNc and PerCP-conjugated CD3 mAb (Becton Dickinson) for 30
minutes at 5uC.
Cells were acquired using flow cytometry on a FACS Calibur
(Becton Dickinson) machine and were analyzed using FlowJo
software by gating on the lymphocyte population in forward
scatter (FSC) and side scatter (SSC), and gating on live cell
populations. Gating was then performed for CD8HI+ population to
determine if they were antigen specific and producing IFNc.
These gated statistics were used and the specific responses (i.e. the
percentage of positive stimulated cells minus the percentage of
positive unstimulated cells) were displayed in a histogram. The
data shown are representative of triplicate experiments.
Statistical Methods
A Mann-Whitney test was used for all comparisons between
groups, areas under the curve and comparisons between early and
late time points (week 1 and week 52) between groups, and the
Binomial method was used to estimate the confidence intervals
using STATA 9 [32]
Results
Recruitment and Demographics
Subjects were recruited from February 2004 to November 2005
for the BCG-BCG group, and fromMarch 2003 to June 2006 for the
BCG-MVA85A group. All subjects were followed up for safety and
immunogenicity for 24 weeks after vaccination, with an additional
visit at 52 weeks for 12 subjects from the BCG-BCG regime and 13
subjects from the BCG-MVA85A regime. There was 1 (7%) of 14
subjects in the BCG-BCG group born outside the UK, whereas 7
(33%) of 21 subjects in the BCG-MVA85A group were born outside
the UK. Three (21%) of BCG-BCG subjects had significant travel
history compared with 2 (10%) of BCG-MVA85A subjects.
Safety of BCG-BCG Vaccination Compared With BCG-
MVA85A Vaccination
The BCG-BCG and BCG-MVA85A regimens were well
tolerated with no serious or severe vaccine related systemic
adverse events. There were no marked differences in local and
systemic adverse events between BCG-BCG (n=14) and BCG-
MVA85A (n= 21) vaccination regimens.
All subjects in the BCG-BCG and BCG-MVA85A regimens
experienced some mild local adverse events related to the
vaccination. This included redness, pain and induration that was
experienced by all subjects in both regimens, with some subjects
also experiencing pruritus (Table 2A).
All systemic adverse events reported were mild in severity. The
most common systemic adverse events were headache (5 (36%) of
14 subjects receiving BCG-BCG and 8 (38%) of 21 subjects
receiving BCG-MVA85A), and myalgia (5 (36%) of 14 subjects
receiving BCG-BCG and 5 (24%) of 21 subjects receiving BCG-
MVA85A). The adverse event profiles were comparable between
the two vaccine regimens (Table 2A and B).
BCG-MVA85A induced significantly stronger cellular
immune responses to antigen 85 protein and antigen
85A SPP than BCG-BCG vaccination
The immune responses to PPD, antigen 85, and antigen 85A
SPP were compared between subjects in the BCG-BCG and
Table 2. Local and Systemic Adverse Events in Subjects After
the BCG-BCG or BCG-MVA85A Vaccination Regimen.
A: Local Adverse Events
Adverse event BCG-BCG (n=14) BCG–MVA85A
(n=21)
Redness 100% (14) 100% (21)
Pruritus 64% (9) 48% (10)
Pain 100% (14) 100% (21)
Induration 100% (14) 100% (21)
B: Systemic Adverse Events
Adverse event BCG-BCG (n=14) BCG–MVA85A
Long boosting
interval (n= 21)
Fever 0% (0) 5% (1)
Feverish 14% (2) 24% (5)
Arthralgia 29% (4) 14% (3)
Headache 36% (5) 38% (8)
Myalgia 36% (5) 24% (5)
Nausea 7% (1) 5% (1)
Diarrhoea 0% 0% (0)
Vasovagal syncope 0% 0% (0)
Axillary LN 14% (2) 5% (1)
Alterations in haem/
biochem
7% (1) 0% (0)
Infection at injection site 7% (1) 5% (1)
doi:10.1371/journal.pone.0005934.t002
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BCG-MVA85A trials in PBMC at various time points over the 52-
week post-vaccination period. In the BCG-BCG subjects, a strong
cellular immune response to PPD was elicited at 1-week post-
vaccination, resulting in an increase in IFNc ELISpot responses
(median 824 spot forming cells (SFC)/106 peripheral blood
mononuclear cells (PBMC)) above levels observed at screening
(median 205 SFC/106 PBMC; Figure 2A). The cellular immune
response was lower by 12 weeks post-vaccination (median 467
Figure 2. Median IFNc ELISpot Responses to PPD, antigen 85A protein, and SPP, up to 52 Weeks Post-Vaccination. Median IFNc
ELISpot responses were assessed for PBMC from subjects in the BCG-BCG and BCG-MVA85A vaccination regimens against: (A) Tuberculin PPD; (B)
Purified antigen 85 protein; (c) summed pooled peptide (SPP) of antigen 85A peptides. (d) A dot plot of AUC0–52weeks values calculated for PPD,
antigen 85A protein, and SPP, and statistical analyses performed using Mann-Whitney test to compare results from BCG-BCG and BCG-MVA85A
subjects. The results demonstrate significantly higher responses to antigen 85A protein (p = 0.009) and SPP (p = 0.0001) in BCG-MVA subjects
compared with BCG-BCG subjects.
doi:10.1371/journal.pone.0005934.g002
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SFC/106 PBMC), and reached a plateau at these levels which
persisted for at least 52 weeks after vaccination (median 402 SFC/
106 PBMC). Similarly, in BCG-MVA85A subjects, the peak
response to PPD was observed 1-week post-vaccination (median
783 SFC/106 PBMC). These levels dropped at 12 weeks post-
vaccination (median 223 SFC/106 PBMC), increasing marginally
at 52 weeks (median 347 SFC/106 PBMC).
The response to antigen 85 protein in the BCG-BCG subjects
was lower than the PPD response; peaking at 1 week post-
vaccination (median 340 SFC/106 PBMC) from screening
(median 105 SFC/106 PBMC). A low level response to this
antigen continued to be observed throughout the 52-week post-
vaccination period (Figure 2B). In contrast, there was a marked
increase in response to antigen 85 protein in the BCG-MVA85A
subjects at 1-week post-vaccination (median 790 SFC/106 PBMC)
over values observed at screening (median 27 SFC/106 PBMC;
Figure 2B). The response to antigen 85A declined up to 12-weeks
post-vaccination (median 113 SFC/106 PBMC), and response
levels were marginally higher at 52 weeks (median 237 SFC/106
PBMC).
In BCG-BCG subjects, the response to SPP increased at 1 week
post-vaccination (median 236 SFC/106 PBMC) compared with
screening (median 102 SFC/106 PBMC). The response was
reduced to baseline levels (median 95 SFC/106 PBMC) at 8-weeks
post-vaccination, where this plateau continued to 52 weeks
(median 34 SFC/106 PBMC). In BCG-MVA85A subjects, the
response to SPP increased markedly at 1 week post-vaccination
(median 2147 SFC/106 PBMC), compared with values at
screening (median 13 SFC/106 PBMC). The response to SPP
declined by 12 weeks (median 390 SFC/106 PBMC), and then
increased marginally by 52 weeks post-vaccination (median 506
SFC/106 PBMC).
To analyse the effect of the vaccine regimens over the 52-week
post-vaccination period, an area under the curve (AUC) analysis of
the IFNc ELISpot responses was performed on subjects present at
all time points (1, 2, 4, 8, 12, 24, and 52 weeks). The results
demonstrated that the boosting effect of MVA85A (n= 13) was
significantly greater than the booster effect of BCG (n= 12) in
enhancing the cellular response to antigen 85A (p= 0.009) and
SPP (p = 0.0001) over the 52-week period (Figure 2D and Table 3).
The response to PPD was not significantly different between the
BCG–BCG and BCG–MVA85A groups (Table 3).
1 Week Post-Vaccination
To examine the significance of the peak effect of the vaccination
regimens at 1-week post-vaccination, statistical analysis of the
cellular immune responses to PPD, antigen 85A protein and SPP
was performed (BCG:BCG n=21 BCG:MVA85A n= 14). A
strong cellular immune response was observed for PPD-specific
PBMC in both BCG-BCG and BCG-MVA85A subjects at 1 week
after vaccination (median 707 SFC/106 PBMC and 824 SFC/106
PBMC, respectively), with no significant differences in response to
PPD between the 2 groups (p = 0.95; Figure 3A). In contrast, at 1
week after vaccination, a significantly higher response for PBMC
from BCG-MVA85A subjects was observed against antigen 85A
protein (median 790 SFC/106 PBMC) and SPP (median 2147
SFC/106 PBMC) than in PBMC from BCG-BCG subjects
(median 340 SFC/106 PBMC against antigen 85A protein,
p = 0.002, and median 236 SFC/106 PBMC against SPP,
p,0.0001; Table 4, and Figure 3A).
52 Weeks Post-Vaccination
To determine the level of cellular immune responses at the end
of the follow-up period, 52-week post-vaccination samples were
examined, (BCG:BCG n=12, BCG:MVA85A n= 13). Statistical
analysis of subjects at 52-weeks post-vaccination demonstrated a
moderate response to PPD in PBMC from BCG-BCG subjects
(median 402 SFC/106 PBMC) and BCG-MVA85A subjects
(median 347 SFC/106 PBMC), with no significant difference. A
significantly greater antigen 85A specific cellular immune response
was detected in PBMC from BCG-MVA85A subjects (median 237
SFC/106 PBMC to recombinant protein and median 506 SFC/
106 PBMC to the SPP) than in PBMC from BCG-BCG subjects
(median 83 SFC/106 PBMC against antigen 85A, p= 0.0003, and
34 SFC/106 PBMC against SPP, p = 0.0001; Table 4 and
Figure 3B).
Dendritic cell mediated amplification of IFNc secreting,
antigen 85A peptide specific, CD8+ T cells from PBMC
In the five HLA-A2+ BCG-BCG subjects studied in this
analysis, only one subject had very low levels of IFNc secreting,
CD8+ T cells recognising KLIANNTRV (1.5% of total CD8
population)at one time point (4-weeks) post-vaccination (Figure 4).
In contrast, in the eight HLA-A2+ BCG-MVA85A subjects, IFNc
secreting, CD8+ T cells recognising KLIANNTRV were detect-
able at 2- and 4-weeks post-vaccination in 4 (50%) of 8 subjects, at
levels up to approximately 10-fold higher than those observed for
BCG-BCG subjects (up to 14% total CD8 population).
Discussion
In this current study, revaccination with BCG was well tolerated
with no unexpected or serious adverse events up to 52 weeks post-
vaccination. This was similar to the adverse event profile observed
in subjects in a previously reported trial using the BCG-MVA85A
vaccine regimen [24].
Vaccination with BCG has variable efficacy, failing to protect
against pulmonary disease in adults, whilst affording protection in
Table 3. AUC0–52weeks IFNc ELISpot Responses in BCG-BCG and BCG-MVA85A Subjects.
Outcome of area under
the curve 0–52 week BCG-MVA85A BCG-BCG
Difference in
medians (95% CI) a P-valueb
n Median (IQR) n Median (IQR)
PPD 13 16736 (11057, 26379) 12 24201 (16408, 32634) 25603 (215628 to 3654) 0.23
Antigen 85A 13 12937 (7256, 26401) 12 6193 (4915, 12216) 6446 (1078 to 14982) 0.009
SPP 13 31760 (15978, 74853) 12 4256 (2453, 6697) 24379 (11133 to 65216) 0.0001
IQR= inter quartile range; AUC calculated between baseline and 52 weeks post vaccination.
aestimated using the Binomial method.
bMann-Whitney test.
doi:10.1371/journal.pone.0005934.t003
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childhood [4]. The most widely accepted explanation for the
variable efficacy of BCG in many global trials is that prior
exposure to environmental mycobacteria either inhibits the
replication and development of BCG induced protective immune
response or masks the effect of BCG vaccination by providing a
similar degree of anti-mycobacterial immunity [11,33]. In this
Figure 3. Comparison of IFNc ELISpot Responses in BCG-BCG and BCG-MVA85A Subjects. IFNc ELISpot responses for BCG-BCG and BCG-
MVA85A vaccine regimens at (A) 1 week and (B) 52 weeks post-vaccination. Statistically significant differences between the two vaccination regimens
were assessed using Mann-Whitney test. BCG-MVA85A subjects had significantly greater responses to antigen 85A protein and SPP compared with
BCG-BCG subjects.
doi:10.1371/journal.pone.0005934.g003
Table 4. Statistical Analysis of 1-Week and 52-Week Post-Vaccination IFNc ELISpot Responses in BCG-BCG and BCG-MVA85A
Subjects.
Outcome at 1 week
post-vaccination BCG-MVA85A BCG-BCG
Difference in medians
(95% CI)a P-valueb
n Median (IQR) n Median (IQR)
PPD 21 707 (389, 1653) 14 824 (521, 967) 221 (2328 to 576) 0.95
Antigen 85A 21 790 (422, 1653) 14 340 (182, 464) 427 (167 to 1090) 0.002
SPP 21 2147 (1172, 5084) 14 236 (148, 399) 1939 (1074 to 4520) ,0.0001
Outcome at 52 weeks post-
vaccination
PPD 13 347 (199, 737) 12 402 (277, 517) 26 (2177 to 290) 0.83
Antigen 85a 13 237 (160, 555) 12 83 (20, 142) 190 (74 to 446) 0.0003
SPP 13 506 (214, 921) 12 34 (21, 73) 419 (177 to 854) 0.0001
IQR= inter quartile range.
aestimated using the Binomial method.
bMann-Whitney test.
doi:10.1371/journal.pone.0005934.t004
Figure 4. Dendritic Cell Amplification of TB-Specific, IFNc Producing CD8 T Cells. TB-specific CD8+ T cells producing IFNc in response to an
immunodominant peptide KLIANNTRV, were identified in HLA-A2 positive subjects in the BCG-BCG and BCG-MVA85A vaccine regimens at 2 and 4
weeks. TB-specific CD8+ T cells were not detectable above 0.5% TB-specific CD8+ T cells at the 0, 1, 8, and 24 week timepoints analysed (data not
shown). Values are presented as mean (+SD) and represents triplicate samples.
doi:10.1371/journal.pone.0005934.g004
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current study, the differences in cellular immune responses
between these two vaccine regimens could not be explained by
possible differences in the levels of mycobacterial antigen exposure
at baseline. To confirm there was no difference between
mycobacterial antigen exposure between trials, the trial inclusion
criteria, including baseline Tuberculin skin test responses, were the
same for both trials.
The results from this study provide evidence that there are
elevated cellular immune responses to M.tb antigens following
BCG-BCG and BCG-MVA85A vaccine regimens. The IFNc
ELISpot response to PPD in BCG-BCG subjects was high, and
similar to BCG-MVA85A subjects at both early (week 1) and late
(week 52) time points, and over the 52 weeks period (as determined
by AUC values), with no significant differences observed between
the two vaccine regimes. Boosting BCG with BCG may result in
boosting of many of the different secreted antigens within PPD,
whereas boosting with MVA85A will only result in boosting of the
antigen 85A component of BCG.
In contrast to the PPD responses, in this study, we have shown
that subjects vaccinated with MVA85A have significantly higher
cellular immune responses to antigen 85A protein and antigen
85A SPP at peak (week 1) and plateau (week 52) time points, and
over the 52 week period (as determined by AUC values) than in
BCG-BCG subjects. Studies have demonstrated that reactivity
against antigen 85A [19] and antigen 85B protein [34], invoke a
protective immunity to TB. Immunization with a vaccine
construct that encodes antigen 85A confers protection against
challenge with live TB in small animals [21,22,23].
Although significant differences were observed using the ex vivo
IFNc ELISpot assays, this assay only detected CD4+ T cell
responses. No CD8+ T cell responses have been identified before
this current study. Therefore, we used DC to amplify the low
numbers of CD8+ T cells that were otherwise not detectable, and
compared between boosting regimens. An HLA-A2 restricted
immunodominant peptide (KLIANNTRV) from antigen 85A was
selected to identify MHC class I-restricted, CD8+ T cells.
KLIANNTRV has been shown to be recognised by PBMC
stimulated with BCG in 50% of BCG-vaccinated subjects [30].
Following amplification of CD8+ T cells using DC, we observed
that revaccination with BCG induced detectable, but low
frequency of pentamer (KLIANNTRV)+, IFNc+, CD8+ T cells
at a single time point in only one of 5 HLA-A2+ subjects. The
magnitude (up to 10-fold higher) of CD8+ T cell recognition of the
immunodominant KLIANNTRV peptide was higher in the BCG-
MVA85A subjects, was detectable in 4 of 8 subjects and detectable
at 2 different time points (in 50% of subjects). It is clear that a
higher frequency of CD8+ T cells can be detected in the BCG-
MVA85A regimen than in the BCG-BCG regimen using this
highly sensitive assay. The clinical significance of this enhanced
CD8+ T cell response can only be determined in large scale
efficacy trials. It is possible that the levels of antigen-specific CD8+
T cell responses remain below the limit of detection in BCG-BCG
subjects, but given the increased sensitivity of the DC-mediated
amplification method used in this study, this would imply they are
at very low frequency indeed. The results of this study demonstrate
that DC are a useful and powerful tool in providing the stimulation
required to amplify the low frequency CD8+ T cells in PBMC
samples to detectable levels.
CD8+ T cell responses to mycobacteria have been shown to be
induced through vaccination with BCG in older subjects, or
following latent infection or active disease [30,35,36,37]. However,
the widely held view is that BCG vaccination results in suboptimal
CD8+ T cell responses. Although CD4+ T cells are the
predominant cells controlling TB infection, there is evidence in
animal studies that CD8+ T cells are involved in protection against
TB [23,38,39]. Protection against M. tb, an intracellular pathogen,
probably requires a finely balanced interplay between cells of the
innate and adaptive immune system. CD8+ T cell responses may
play role in the initial control of TB infection and this may be
elicited by presentation from neutrophils during the initial innate
immune response [40,41] or through interactions with neutrophils
and DC [42]. Neutrophils have been shown to cross-present
pathogen-derived and soluble antigens to CD8+ T cells in vivo [42].
This may go some way to explain the differences observed in
whole blood assays where neutrophils are present and may initiate
CD8+ T cell proliferation, compared with PBMC preparations
where neutrophils are not present. Indeed, it has been shown that
CD8+ T cells can be detected by flow cytometry in whole blood
samples from adults [36,37] and infants [43,44] vaccinated with
BCG. Although pentamer (KLIANNTRV)+, IFNc+, CD8+ T
cells could be detected in the BCG-BCG and BCG-MVA85A
subjects in our study, it is possible that other, functional, CD8+ T
cells exist as we have shown in subjects who received BCG-
MVA85A [45]. As these cells occur at low frequency, it may be
possible that the use of whole blood samples coupled with DC
amplification could be used as a powerful tool for amplifying low
frequency CD8+ T cells to asses their functionality.
In summary, the results in this study have demonstrated that in
the BCG-MVA85A vaccination regimen, significantly stronger
cellular immune responses to antigen 85A can be induced
compared with revaccination with BCG-BCG. IFNc is clearly
an important cytokine involved in protection against TB and has
been used as a measure of vaccine ‘‘take’’ [12] in Phase I BCG-
MVA85A clinical trials [24,45,46,47]. As further research is
performed, it is highly likely that other correlates of protection will
emerge. Proofs of concept efficacy trials are due to start in early
2009, and will enable us to evaluate whether enhanced immune
responses following BCG-MVA85A result in improved protection.
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